Celldex Therapeutics (Celldex Therapeutics) FCF Margin % : -803.66% (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celldex Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-33.20 Mil. Celldex Therapeutics's Revenue for the three months ended in Dec. 2023 was $4.13 Mil. Therefore, Celldex Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -803.66%.

As of today, Celldex Therapeutics's current FCF Yield % is -4.56%.

The historical rank and industry rank for Celldex Therapeutics's FCF Margin % or its related term are showing as below:

CLDX' s FCF Margin % Range Over the Past 10 Years
Min: -4478.57 Med: -1460.82 Max: -565.6
Current: -1585.2

During the past 13 years, the highest FCF Margin % of Celldex Therapeutics was -565.60%. The lowest was -4478.57%. And the median was -1460.82%.

CLDX's FCF Margin % is ranked worse than
79.79% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs CLDX: -1585.20

Celldex Therapeutics FCF Margin % Historical Data

The historical data trend for Celldex Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics FCF Margin % Chart

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,319.51

-565.60

-1,336.44

-4,478.57

-1,585.20

Celldex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-1,363.73	-3,014.89	-10,300.75	-1,262.36	-803.66

Competitive Comparison of Celldex Therapeutics's FCF Margin %

For the Biotechnology subindustry, Celldex Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's FCF Margin % falls into.

Celldex Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Celldex Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-109.109	/	6.883
	=	-1,585.20 %

Celldex Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-33.199	/	4.131
	=	-803.66 %

Celldex Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (Celldex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TCE2:Germany

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Executives

Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler	officer: Sen. VP & Ch Scientific Off.	30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh	officer: SVP of Corp. Affairs & Admin.	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young	officer: SVP, Chief Medical Officer	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci	director, officer: President and CEO	66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright	officer: Sr. VP & CCO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin	officer: SVP and CFO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi	officer: SVP of of Regulatory Affairs	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley	officer: SVP, Chief Product Dev Officer	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez	officer: SVP & General Counsel	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114